Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

OBJECTIVE: Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes from normal glucose tolerance (NGT) to abnormal glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, William E., Bundy, Brian N., Anderson, Mark S., Cooney, Laura A., Gitelman, Stephen E., Goland, Robin S., Gottlieb, Peter A., Greenbaum, Carla J., Haller, Michael J., Krischer, Jeffrey P., Libman, Ingrid M., Linsley, Peter S., Long, S. Alice, Lord, Sandra M., Moore, Daniel J., Moore, Wayne V., Moran, Antoinette M., Muir, Andrew B., Raskin, Philip, Skyler, Jay S., Wentworth, John M., Wherrett, Diane K., Wilson, Darrell M., Ziegler, Anette-Gabriele, Herold, Kevan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154649/
https://www.ncbi.nlm.nih.gov/pubmed/36920087
http://dx.doi.org/10.2337/dc22-2200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154649/
https://www.ncbi.nlm.nih.gov/pubmed/36920087
http://dx.doi.org/10.2337/dc22-2200

Ejemplares similares